Suppr超能文献

拉丁美洲医院分离出的革兰氏阳性菌中的抗菌药物耐药性。

Antimicrobial resistance among Gram-positive bacteria isolated in Latin American hospitals.

作者信息

Sader H S, Moet G J, Jones R N

机构信息

JMI Laboratories, North, Liberty, Iowa 52317, USA.

出版信息

J Chemother. 2009 Dec;21(6):611-20. doi: 10.1179/joc.2009.21.6.611.

Abstract

Antimicrobial resistance patterns of the most frequently isolated Gram-positive bacteria in selected Latin American hospitals were evaluated under the auspices of the SENTRY Antimicrobial Surveillance Program. The strains were consecutively collected (one per patient) between January 2003 and December 2008 and tested by reference broth microdilution methods at the monitoring central laboratory (JMI Laboratories, North Liberty, Iowa, USA). A total of 12,324 Gram-positive cocci were analyzed. The organisms were isolated from bloodstream (53.2%) and skin and skin structure infections (16.4%). Resistance to oxacillin (MRSA) was observed in 40.0% of Staphylococcus aureus, varying from 32.7% in Brazil to 49.7% in Chile. Resistance to erythromycin (90.1%), clindamycin (84.4%), and levofloxacin (86.8%) was very high in MRSA. Vancomycin, linezolid and daptomycin were all very active against S. aureus strains tested (>99.9-100.0% susceptible), but daptomycin (MIC(50/90), 0.25/0.5 microg/ml) was four- to eight-fold more potent than three comparators. Vancomycin resistance increased from 5.0% in 2003 to 15.5% in 2008 among enterococci (VRE); the most significant increase occurred among isolates from Brazilian medical centers (from 6.9 to 31.1%). Daptomycin was the most active antimicrobial tested against enterococci in general (MIC(50/90) microg/ml; 100.0% susceptible), followed by linezolid (MIC(50/90), 1/2 microg/ml; 99.9% susceptible), teicoplanin (MIC(50 )and MIC(90 )of <2 microg/ml; 91.3% susceptible), vancomycin (MIC(50/90), 1/8 microg/ml; 89.6% susceptible). In summary, daptomycin and linezolid showed excellent in vitro activity against Gram-positive organisms (12,324) collected in Latin American hospitals, including MRSA, VRE and other multidrug-resistant organisms.

摘要

在哨兵抗菌监测计划的支持下,对拉丁美洲部分医院中最常分离出的革兰氏阳性菌的耐药模式进行了评估。这些菌株于2003年1月至2008年12月期间连续收集(每位患者一株),并在美国爱荷华州北利伯蒂的监测中心实验室(JMI实验室)采用参考肉汤微量稀释法进行检测。共分析了12324株革兰氏阳性球菌。这些微生物分离自血流感染(53.2%)以及皮肤和皮肤结构感染(16.4%)。在40.0%的金黄色葡萄球菌中观察到对苯唑西林的耐药(耐甲氧西林金黄色葡萄球菌,MRSA),在巴西为32.7%,在智利为49.7%。MRSA对红霉素(90.1%)、克林霉素(84.4%)和左氧氟沙星(86.8%)的耐药率非常高。万古霉素、利奈唑胺和达托霉素对所检测的金黄色葡萄球菌菌株均具有很高活性(>99.9 - 100.0%敏感),但达托霉素(MIC(50/90),0.25/0.5微克/毫升)的效力比其他三种对照药物强4至8倍。肠球菌(耐万古霉素肠球菌,VRE)中的万古霉素耐药率从2003年的5.0%增至2008年的15.5%;巴西医疗中心分离出的菌株中增幅最为显著(从6.9%增至31.1%)。总体而言,达托霉素是对肠球菌检测中活性最高的抗菌药物(MIC(50/90)微克/毫升;100.0%敏感),其次是利奈唑胺(MIC(50/90),1/2微克/毫升;99.9%敏感)、替考拉宁(MIC(50)和MIC(90)<2微克/毫升;91.3%敏感)、万古霉素(MIC(50/90),1/8微克/毫升;89.6%敏感)。总之,达托霉素和利奈唑胺对拉丁美洲医院收集的革兰氏阳性菌(12324株),包括MRSA、VRE和其他多重耐药菌,显示出优异的体外活性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验